Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Undergraduate Student Research Awards (USRA)

University of British Columbia

$6,000.00

Response to second- and third-line therapies in children with chronic immune thrombocytopenia

FY 2024-25

Summary
Chronic immune thrombocytopenia (ITP) is an autoimmune disorder resulting in platelet destruction and sometimes causing severe bleeding. Most children who develop ITP recover quickly but in 20%, ITP becomes chronic and presents a management challenge if first-line therapy such as intravenous immunoglobulin (IVIG) or corticosteroids fail to produce complete or sustained rises in platelet count. While pediatric treatment guidelines recommend thrombopoietin receptor agonists (TPO-RA) as second-line therapy, many provincial government insurance programs, due to cost and lack of long-term outcome data, suggest using third-line therapies ahead of TPO-RA despite a lack of compelling evidence of good response. The purpose of this project is to perform a retrospective chart review of children with chronic ITP treated at BC Children's Hospital from 2013-2023 who failed to respond to first-line therapy and assess their response to additional therapy. By reporting these outcomes, we hope to provide clearer direction as to which therapy is the next best alternative when first-line therapy fails. Expected outcomes include determination of: 1) response rate and duration of response to TPO-RA therapy when used as second-line therapy, including the need to discontinue TPO-RA therapy and switch to alternative therapies; 2) response rate and duration of response to third-line therapy (rituximab, mycophenolate mofetil, splenectomy, other medication) when used after failure of first-line therapy, including the proportion of patients who needed to switch to TPO-RA therapy; 3) the proportion of patients who required multiple lines of therapy to manage their chronic ITP; 4) the proportion of patients whose ITP was found to be due to the
Program
Undergraduate Student Research Awards (USRA)
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506711
Name
Rollins Claire
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Response to second- and third-line therapies in children with chronic immune thrombocytopenia
Programtype2
Miscellaneous Programs
Orgnameinp2
University of British Columbia
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Chart Review; Children; Chronic Immune Thrombocytope; First-Line Therapy; Second-Line Therapy
Abstract
Chronic immune thrombocytopenia (ITP) is an autoimmune disorder resulting in platelet destruction and sometimes causing severe bleeding. Most children who develop ITP recover quickly but in 20%, ITP becomes chronic and presents a management challenge if first-line therapy such as intravenous immunoglobulin (IVIG) or corticosteroids fail to produce complete or sustained rises in platelet count. While pediatric treatment guidelines recommend thrombopoietin receptor agonists (TPO-RA) as second-line therapy, many provincial government insurance programs, due to cost and lack of long-term outcome data, suggest using third-line therapies ahead of TPO-RA despite a lack of compelling evidence of good response. The purpose of this project is to perform a retrospective chart review of children with chronic ITP treated at BC Children's Hospital from 2013-2023 who failed to respond to first-line therapy and assess their response to additional therapy. By reporting these outcomes, we hope to provide clearer direction as to which therapy is the next best alternative when first-line therapy fails. Expected outcomes include determination of: 1) response rate and duration of response to TPO-RA therapy when used as second-line therapy, including the need to discontinue TPO-RA therapy and switch to alternative therapies; 2) response rate and duration of response to third-line therapy (rituximab, mycophenolate mofetil, splenectomy, other medication) when used after failure of first-line therapy, including the proportion of patients who needed to switch to TPO-RA therapy; 3) the proportion of patients who required multiple lines of therapy to manage their chronic ITP; 4) the proportion of patients whose ITP was found to be due to the
Competitiondate
202405
Approvedterm2
0 yr 6 mths
Pinamesdelim
Rollins, Claire
Approvedterm
0 an 6 mois
Cihrcontribution2
~ $6,000~ $0~
University of British Columbia - $6,000 Grant (2024-2… | Canada Spends